Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...
PetroChina Company Limited ["PetroChina" or the "Company", (HKSE: 00857, SSE: 601857)] announced that the Company proactively responded to the evolving landscape, boosted oil and gas exploration and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback